hackint0sh/New-Dataset huggingface dataset:
nctId: NCT06327256 id: 1509-0002 id: 2023-509293-29-00 type: REGISTRY domain: CTIS id: U1111-1299-6907 type: REGISTRY domain: WHO International Clinical Trials Registry Platform (ICTRP) briefTitle: A Study in Healthy People to Test How Well Different Doses of BI 3000202 Are Tolerated and How They Affect the Way the Body Handles Midazolam overallStatus: RECRUITING date: 2024-03-28 date: 2024-09-27 date: 2024-09-27 date: 2024-03-25 date: 2024-04-12 name: Boehringer Ingelheim class: INDUSTRY briefSummary: The aim of this trial is to investigate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) following multiple rising doses of BI 3000202 and to investigate the effect of BI 3000202 on the metabolism of midazolam. conditions: Healthy studyType: INTERVENTIONAL phases: PHASE1 allocation: RANDOMIZED interventionModel: SEQUENTIAL interventionModelDescription: The multiple rising dose part of the trial will be conducted in a parallel group assignment. The effect of midazolam interaction will be assessed sequentially. primaryPurpose: TREATMENT masking: TRIPLE maskingDescription: The multiple rising dose part of the trial will be blinded to the participants and investigators . The effect of midazolam will be assessed open label. whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR count: 40 type: ESTIMATED name: BI 3000202 name: Placebo name: Midazolam measure: Percentage of subjects with drug-related adverse events measure: Area under the concentration-time curve of BI 3000202 in plasma over the dosing interval 0 to 12 hours (AUC0-12) measure: Maximum measured concentration BI 3000202 in plasma (Cmax) measure: Area under the concentration-time curve of BI 3000202 in plasma over a uniform dosing interval τ (AUCτ,ss) at steady state measure: Maximum measured concentration of BI 3000202 in plasma (Cmax,ss) at steady state measure: Time from dosing to the maximum measured concentration of BI 3000202 in plasma (tmax,ss) at steady state measure: Area under the concentration-time curve of midazolam in plasma over the time interval from 0 to the last quantifiable data point (AUC0-tz) after a single dose measure: Maximum measured concentration of midazolam in plasma (Cmax) after a single dose sex: ALL minimumAge: 18 Years maximumAge: 55 Years stdAges: ADULT facility: SGS Life Science Services - Clinical Research status: RECRUITING city: Edegem zip: 2650 country: Belgium name: Boehringer Ingelheim role: CONTACT phone: 080049616 email: belgique@bitrialsupport.com lat: 51.15662 lon: 4.44504 hasResults: False
nctId: NCT06327243 id: TUMRHS briefTitle: The Effects of Kinesio Taping on Pain, Range of Motion, and Functional Performance in People With Knee Osteoarthritis overallStatus: RECRUITING date: 2024-03-01 date: 2024-04-01 date: 2024-04-30 date: 2024-03-25 date: 2024-03-25 name: Taibah University class: OTHER briefSummary: The goal of this clinical trial is to evaluate the effectiveness of Kinesio Taping in individuals with knee osteoarthritis (KOA). KOA is a common condition that can lead to pain, stiffness, and decreased mobility. The main questions it aims to answer are:
Researchers will compare the group that receives Kinesio Taping with the group that receives sham (placebo) taping to see if there are significant differences in pain reduction and improvements in movement and daily function. conditions: Knee Osteoarthritis studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: In a randomized and single-blinded approach, participants are divided into two groups. One group receives actual Kinesio taping, while the other undergoes a sham procedure, with neither group aware of their specific treatment type to ensure unbiased results. primaryPurpose: TREATMENT masking: SINGLE maskingDescription: Participants will not know if they are receiving the actual Kinesio Taping (KT) treatment or a sham taping. The KT will be applied following the correct standards for the rectus femoris muscle, including appropriate stretching. Conversely, the placebo taping will be applied horizontally across the muscle fibers without any stretching. The therapists applying the tape will know which treatment each participant is allocated to ensure that the application of either the real KT or the placebo taping aligns with the study's protocol. whoMasked: PARTICIPANT count: 30 type: ESTIMATED name: Elastic tape ( kinesio tape) name: Sham Taping measure: Pain (Visual analog scale) measure: Knee range of motion measure: Timed up and go test measure: The 50-foot Walk measure: Knee Osteoarthritis Outcome Score (KOOS) sex: ALL minimumAge: 40 Years maximumAge: 70 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Taibah University status: RECRUITING city: Medina zip: 42353 country: Saudi Arabia name: President of the university role: CONTACT email: tawasul@taibahu.edu.sa name: Marwan MA Aljohani, Phd role: CONTACT email: mmjohani@taibahu.edu.sa lat: 24.46861 lon: 39.61417 hasResults: False
nctId: NCT06327217 id: OC-2023-009 briefTitle: Long Term Results After Hip Arthroscopy overallStatus: NOT_YET_RECRUITING date: 2024-04-01 date: 2025-03-01 date: 2025-03-01 date: 2024-03-25 date: 2024-03-25 name: Reinier Haga Orthopedisch Centrum class: OTHER briefSummary: A common cause of hip joint pain in the young and active population is femoroacetabular impingement (FAI) syndrome. if FAI is left untreated, the changed morphology will have a negative effect on the existing joint and will contribute to the development of osteoarthritis (OA). Hip arthroscopy is the first choice of operative treatment for FAI. While hip arthroscopy improves the patient reported outcome measures (PROMs), the influence of this treatment on the contribution to the development of osteoarthritis after FAI is to the best of our knowledge still unknown. conditions: Femoro Acetabular Impingement studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 451 type: ESTIMATED name: Bilateral hip x-ray name: Questionnaires measure: To evaluate the degree of osteoarthritis 5 to 10 years after a hip arthroscopy in comparison with the non-operative side. measure: To evaluate the change in degree of osteoarthritis at 5 to 10 years after a hip arthroscopy in comparison with preoperative/perioperative. measure: To report incidence of total hip replacement within 5 to 10 years after a hip arthroscopy. measure: To determine the functional outcome of patients and, to determine what factors contribute to a good functional outcome 5/10 years after hip arthroscopy. measure: To determine the inter-rater and intra-rater agreement of the Kellgren and Lawrence OA score. measure: To determine patient satisfaction 5-10 years after hip arthroscopy. sex: ALL minimumAge: 16 Years stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT facility: Reinier Haga Orthopedic Center city: Zoetermeer zip: 2725 NA country: Netherlands lat: 52.0575 lon: 4.49306 hasResults: False
nctId: NCT06327204 id: Low Level laser 24 briefTitle: Efficacy of Different Low Level Laser Therapy Sessions overallStatus: COMPLETED date: 2023-03-01 date: 2023-10-01 date: 2023-12-01 date: 2024-03-25 date: 2024-03-25 name: October 6 University class: OTHER briefSummary: Myofascial pain dysfunction syndrome is one of the common causes of non-odontogenic pain in the head and neck region. It accounts for 40-60% of the adult population. Different treatment modalities had been reported to release the trigger point within the muscles of mastication in order to reduce pain and allow recovery of the function. conditions: Myofascial Pain Syndrome studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: SINGLE whoMasked: OUTCOMES_ASSESSOR count: 90 type: ACTUAL name: 940-nm diode laser / one session name: 940-nm diode laser / two session name: 940-nm diode laser/ three session measure: pain score measure: maximum mouth opening measure: quality of life questioner sex: ALL minimumAge: 18 Years maximumAge: 60 Years stdAges: ADULT facility: Faculty of Dentistry, October 6 University city: Cairo zip: 21523 country: Egypt lat: 30.06263 lon: 31.24967 hasResults: False
nctId: NCT06327191 id: 23-CRFG-21 id: 23-CRFG-21 type: OTHER domain: Clinical Research Facility Galway (CRFG) study number briefTitle: EMERGE Mothers and Kids overallStatus: NOT_YET_RECRUITING date: 2024-03 date: 2025-12 date: 2025-12 date: 2024-03-25 date: 2024-03-25 name: National University of Ireland, Galway, Ireland class: OTHER briefSummary: The EMERGE Mothers and Kids study is a follow-up to the EMERGE trial of women with GDM (N=535) that aimed to determine the effect of the addition of metformin compared to placebo on insulin initiation rates, maternal weight gain and perinatal morbidity and mortality.
4. to determine whether treatment with metformin during pregnancy, in women with GDM, leads to a reduction in adiposity in the offspring at follow up as measured by anthropometric measurements and sum of skinfolds. conditions: Gestational Diabetes studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: CROSS_SECTIONAL count: 321 type: ESTIMATED name: No intervention as the study is observational. measure: To assess if treatment of GDM with metformin during pregnancy compared to placebo reduces the risk of disorders of glucose metabolism at follow up.. measure: To assess if treatment of GDM with metformin during pregnancy compared to placebo reduces the risk of metabolic syndrome. measure: To assess if treatment of GDM with metformin during pregnancy compared to placebo reduces rates of OW and OB at follow up. measure: To assess if treatment of GDM with metformin during pregnancy compared to placebo reduces the risk of hypertension. measure: To examine the associations of GDM diagnosis, sum of fasting, 1-hour, and 2-hour glucose z-scores after 75-g load, insulin sensitivity, and lipid levels at 24-32 weeks' gestation with lipid levels 3-6 years postpartum. measure: To determine whether treatment with metformin during pregnancy, in women with GDM, leads to a reduction in adiposity in the offspring at follow up as measured by anthropometric measurements and sum of skinfolds. sex: FEMALE minimumAge: 18 Years maximumAge: 50 Years stdAges: ADULT hasResults: False
nctId: NCT06327178 id: NFEC-2023-520 briefTitle: Abscopal Effects of Stereotactic Body Radiotherapy in Metastatic Clear Renal Cell Carcinoma overallStatus: RECRUITING date: 2023-10-01 date: 2024-01-31 date: 2024-04-30 date: 2024-03-25 date: 2024-03-26 name: Nanfang Hospital, Southern Medical University class: OTHER briefSummary: Prior research has indicated that stereotactic body radiotherapy (SBRT) can effectively trigger systemic anti-tumor immune response. The goal of this observational study is to learn about abscopal effects of stereotactic body radiotherapy in patients of metastatic clear renal cell carcinoma. The primary objective was to assess the objective response rate (ORR) and complete response (CR) in non-irradiated lesions, and incidence of adverse events (AEs). conditions: Abscopal Effects of Stereotactic Body Radiotherapy studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: RETROSPECTIVE count: 20 type: ESTIMATED measure: Objective Response Rate sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Nanfang Hospital, Southern Medical University status: RECRUITING city: Guangzhou state: Guangdong zip: 510515 country: China name: Guozhu Xie role: CONTACT email: xieguozhu@126.com lat: 23.11667 lon: 113.25 hasResults: False
nctId: NCT06327165 id: 1-2023-0072 briefTitle: Predictability of ANI (Analgesia Nociception Index) for Spinal Hypotension overallStatus: RECRUITING date: 2024-03-18 date: 2024-12-31 date: 2024-12-31 date: 2024-03-25 date: 2024-03-27 name: Yonsei University class: OTHER briefSummary: Spinal anesthesia is widely accepted as the anesthetic method of choice for Cesarean section. However, the incidence of spinal hypotension is 50-70%, and the decrease in blood pressure is often rapid and severe. Heart rate variability is influenced by various factors such as the sympathetic nervous system, parasympathetic nervous system, temperature regulation, baroreflex, and endocrine regulation, but high frequency heart rate variability above 0.15 Hz very specifically reflects the parasympathetic nervous system. The ANI monitor calculates heart rate variability mediated by changes in the parasympathetic nervous system. This study aims to determine whether ANI monitor can predict hypotension in patients undergoing a caesarean section under spinal anaesthesia while applying the preemptive vasopressor phenylephrine infusion protocol. conditions: Cesarean Section conditions: Spinal Anesthesia studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 40 type: ESTIMATED name: observation measure: predictive value of ANI monitor for spinal hypotension during cesarean delivery measure: Optimal cutoff value of ANI level for predicting occurrence of hypotension sex: FEMALE minimumAge: 20 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Yonsei University Health system, Severance Hospital status: RECRUITING city: Seoul country: Korea, Republic of name: Seung Hyun Kim, Associate Professor role: CONTACT phone: 82-2-2224-1055 email: anesshkim@yuhs.ac lat: 37.566 lon: 126.9784 hasResults: False
nctId: NCT06327152 id: 2659 briefTitle: Caffeine Use in the Management of Preterm Infants overallStatus: RECRUITING date: 2024-02-22 date: 2026-12-31 date: 2026-12-31 date: 2024-03-25 date: 2024-03-26 name: University of California, Irvine class: OTHER briefSummary: This study aims to assess whether extending the duration of caffeine therapy will help preterm infants achieve full oral feeding faster. conditions: Apnea of Prematurity studyType: INTERVENTIONAL phases: PHASE2 allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: This is a randomized, double-blinded, placebo-controlled trial of 40 preterm infants born at less than or equal to 32 weeks and 0 days gestation. Infants will be randomized to receive either caffeine or placebo for up to maximum of additional four (4) weeks after meeting clinical criteria to come off caffeine. primaryPurpose: TREATMENT masking: DOUBLE maskingDescription: Families, nurses, therapists, and doctors will be blinded. Only pharmacy will be unblinded and know which subjects are in each treatment arm. whoMasked: PARTICIPANT whoMasked: INVESTIGATOR count: 40 type: ESTIMATED name: Caffeine name: Sterile Water Placebo measure: Time to full feeds measure: Time to discharge measure: Post menstrual age (PMA) at time of discharge measure: Number of significant cardiopulmonary events measure: Weight change sex: ALL minimumAge: 1 Day maximumAge: 40 Weeks stdAges: CHILD facility: UC Irvine Medical Center status: RECRUITING city: Orange state: California zip: 92868 country: United States name: Cherry Uy, MD role: CONTACT phone: 714-456-6933 email: ccuy@hs.uci.edu name: Cherry Uy, MD role: PRINCIPAL_INVESTIGATOR name: Ernest Lai, MD role: SUB_INVESTIGATOR name: Muhammad Aslam, MD role: SUB_INVESTIGATOR lat: 33.78779 lon: -117.85311 hasResults: False
nctId: NCT06327139 id: CTRIAL 23-24 briefTitle: Optimising Patient Experience in Head and Neck Radiotherapy acronym: OPEN overallStatus: RECRUITING date: 2024-01-02 date: 2025-05 date: 2025-07 date: 2024-03-25 date: 2024-03-25 name: Irish Research Radiation Oncology Group class: NETWORK briefSummary: This study is a phase III, randomized, single-centre, multiple arm trial examining the set-up accuracy of three different types of immobilization methods for head and neck cancer patients receiving radical radiation therapy. The methods of immobilization under investigation in this study are two types of open faced head and neck masks compared with the convention closed faced head and neck mask. Patients receiving treatment using an open faced mask will have their intra fraction motion monitored through the use of intra fraction surface guided monitoring. The study aims to determine the set-up accuracy of the three types of immobilization through measuring the magnitude of the translational corrections on the daily cone beam computed tomography (CBCT). To be eligible for the study a patient must be planned to receive a minimum of 30 fractions of head and neck radiation therapy.
Patients distress levels associated with each type of immobilization device will be measured using the psychological measure General Health Questionnaire-12 (GHQ-12) which will be collected at the beginning and end of their course of radiation therapy treatment. conditions: Head and Neck Cancer studyType: INTERVENTIONAL phases: PHASE3 allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: This study is a phase III, randomized, single-centre, multiple arm trial of immobilization methods for head and neck cancer patients receiving radical radiation therapy. A faceless three point head and neck mask in conjunction with intra fraction surface guided monitoring, a faceless five point mask in conjunction with intra fraction surface guided monitoring and a conventional closed face five point mask without the use of intra fraction surface guided monitoring are being investigated in this study. The set-up accuracy will be based on the magnitude of the translational corrections measured prior to delivery of each radiation therapy fraction. primaryPurpose: TREATMENT masking: NONE count: 201 type: ESTIMATED name: Conventional 5 point closed face immobilisation mask. name: 5 point open face immobilization mask name: 3 point open face immobilization mask measure: The setup accuracy of each immobilization device will be measured based on the magnitude of the translational corrections measured in millimeters prior to delivery of each radiation therapy fraction. measure: Estimate of distress levels during the first week and during the final week of the participants course of radiation therapy using the psychological measure General Health Questionnaire-12 (GHQ-12). sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: St. Luke's Radiation Oncology Network status: RECRUITING city: Dublin zip: D06 HH36 country: Ireland name: Roisin O Maolalai, BSc role: CONTACT phone: 0035314065458 email: Roisin.OMaolalai@slh.ie name: Emma Noone, BSc MA role: CONTACT phone: 003534065467 email: Emma.Noone@slh.ie name: Sinead Brennan, FFR RCSI role: PRINCIPAL_INVESTIGATOR lat: 53.33306 lon: -6.24889 hasResults: False
nctId: NCT06327126 id: BFHHZS20240001 briefTitle: Efficacy and Safety of Single-session Endoscopic Stone Extraction overallStatus: RECRUITING date: 2024-01-01 date: 2024-05-01 date: 2024-05-01 date: 2024-03-25 date: 2024-04-18 name: Beijing Friendship Hospital class: OTHER briefSummary: This is a retrospective study, including approximately 600 patients with acute cholangitis accompanied with choledocholithiasis, who treated with single-session or two-session endoscopic stone extraction at Beijing friendship hospital. The investigators assessed the outcomes of single-stage and two-stage endoscopic stone extraction. conditions: Choledocholithiasis With Acute Cholangitis studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: RETROSPECTIVE count: 600 type: ESTIMATED name: two-session ERCP name: single-session ERCP measure: Success rate of complete stone removal measure: ERCP-related complication rate measure: Length of stay measure: Hospital expenses sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Beijing Friendship Hospital status: RECRUITING city: Beijing state: Beijing zip: 100050 country: China name: Wei Jiang role: CONTACT phone: 18663186116 email: jfw899w@outlook.com lat: 39.9075 lon: 116.39723 hasResults: False
nctId: NCT06327113 id: IRB#23-001248 briefTitle: Antibiotic Tumescent For Chronic Wounds acronym: TAI overallStatus: NOT_YET_RECRUITING date: 2024-03-25 date: 2027-03-25 date: 2028-03-25 date: 2024-03-25 date: 2024-03-25 name: University of California, Los Angeles class: OTHER briefSummary: Chronic non-healing wounds are becoming an increasingly more common problem. Eligible, consenting patients with chronic leg wounds will either continue to the standard of care or will be randomized to the treatment cohort where antibiotic solution will be injected in the area around the wound. All patients will continue standard wound care as dictated by the wound care clinic. Subjects of both the control and treatment will have approximately 6 study specific visits that may or may not coincide with previously schedule wound care clinic visits. As these specified visits wound size and healing will be documented and patients will complete surveys. The study will conclude for the subject after approximately 6 months. Again, these patients may continue standard wound care but will no longer have study obligations. conditions: Non-healing Wound studyType: INTERVENTIONAL phases: PHASE2 allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: This is a single center, prospective, comparative interventional, two-arm parallel group, randomized, clinical safety and efficacy trial comparing a group receiving standard wound care with tumescent antibiotic injection (TAI) with a control group receiving standard wound care primaryPurpose: TREATMENT masking: NONE count: 60 type: ESTIMATED name: CeFAZolin Injectable Solution measure: Primary Objective - Assess the rate of occurrence and severity of adverse events and their relationship to TAI measure: Secondary Objective - To evaluate wound size and closure. measure: Secondary Objective - Chronic-wound-related pain measure: Secondary Objective - Rating Quality of life measure: Exploratory Objectives - Assess the number of chronic wound-related complications (increased wound sizes, infections, dermatitis). measure: Exploratory Objectives - Assess the number of clinical signs of infection in participants. measure: Exploratory Objectives - Determine the species of pathogenic bacteria present in wound. sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06327100 id: 2023-0934 id: NCI-2024-02551 type: OTHER domain: NCI-CTRP Clinical Registry briefTitle: Open Label Phase 2 Study of Tasquinimod in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (Post-PV MF), or Post-Essential Thrombocytosis Myelofibrosis (Post-ET MF) overallStatus: NOT_YET_RECRUITING date: 2024-09-30 date: 2029-05-01 date: 2031-05-01 date: 2024-03-25 date: 2024-04-29 name: M.D. Anderson Cancer Center class: OTHER name: Active Biotech AB briefSummary: To learn if tasquinimod either alone or in combination with ruxolitinib can help to control PMF, post-PV MF, or post-ET MF. conditions: Primary Myelofibrosis conditions: Post-polycythemia Vera Myelofibrosis conditions: Post-Essential Thrombocytosis Myelofibrosis studyType: INTERVENTIONAL phases: PHASE2 allocation: NON_RANDOMIZED interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 33 type: ESTIMATED name: Ruxolitinib name: Tasquinimod measure: Safety and adverse events (AEs) sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: MD Anderson Cancer Center city: Houston state: Texas zip: 77030 country: United States name: Lucia Masarova, MD role: CONTACT phone: 832-750-4211 email: lmasarova@mdanderson.org name: Lucia Masarova, MD role: PRINCIPAL_INVESTIGATOR lat: 29.76328 lon: -95.36327 hasResults: False